ES2749186T3 - Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas - Google Patents
Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas Download PDFInfo
- Publication number
- ES2749186T3 ES2749186T3 ES15720077T ES15720077T ES2749186T3 ES 2749186 T3 ES2749186 T3 ES 2749186T3 ES 15720077 T ES15720077 T ES 15720077T ES 15720077 T ES15720077 T ES 15720077T ES 2749186 T3 ES2749186 T3 ES 2749186T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- alkyl
- heterocyclyl
- compound
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c(cc1O*)ccc1N Chemical compound *c(cc1O*)ccc1N 0.000 description 6
- SNCKTQVOUKGXQR-LICLKQGHSA-N CCOc(c(C)c(c(/N=C/N(C)C)c1)C#N)c1N=S(C)(C)=O Chemical compound CCOc(c(C)c(c(/N=C/N(C)C)c1)C#N)c1N=S(C)(C)=O SNCKTQVOUKGXQR-LICLKQGHSA-N 0.000 description 1
- VKJHBYYPRYIJCC-LLVKDONJSA-N C[C@H](C(NCC(F)(F)F)=O)Oc(cc(cc1)Cl)c1Nc1c(c(C)c(c(Br)c2)OC)c2ncn1 Chemical compound C[C@H](C(NCC(F)(F)F)=O)Oc(cc(cc1)Cl)c1Nc1c(c(C)c(c(Br)c2)OC)c2ncn1 VKJHBYYPRYIJCC-LLVKDONJSA-N 0.000 description 1
- FOGVEYPAPSELLE-LLVKDONJSA-N C[C@H](C(NCC(F)(F)F)=O)Oc(cc(cc1)F)c1Nc(ncnc1cc2N=S(C)(C)=O)c1c(Cl)c2OC Chemical compound C[C@H](C(NCC(F)(F)F)=O)Oc(cc(cc1)F)c1Nc(ncnc1cc2N=S(C)(C)=O)c1c(Cl)c2OC FOGVEYPAPSELLE-LLVKDONJSA-N 0.000 description 1
- VIICQQDEGZMPNA-OAHLLOKOSA-N C[C@H](C(NCC(F)(F)F)=O)Oc(cc(cc1)F)c1Nc1ncnc(cc2N=S3(CCCC3)=O)c1c(C)c2OC Chemical compound C[C@H](C(NCC(F)(F)F)=O)Oc(cc(cc1)F)c1Nc1ncnc(cc2N=S3(CCCC3)=O)c1c(C)c2OC VIICQQDEGZMPNA-OAHLLOKOSA-N 0.000 description 1
- GZXQEMJFYVJYGP-ZCFIWIBFSA-N C[C@H](C(NCC(F)(F)F)=O)Oc(cc(cc1)F)c1[N+]([O-])=O Chemical compound C[C@H](C(NCC(F)(F)F)=O)Oc(cc(cc1)F)c1[N+]([O-])=O GZXQEMJFYVJYGP-ZCFIWIBFSA-N 0.000 description 1
- VHVBDGHFDASHSR-OVSMBABESA-N Cc(c1c(cc2N=S3(CCC3)=O)ncnc1Nc(ccc(F)c1)c1O[C@H](CO[C@@H]13)[C@H]1OC[C@H]3OC)c2OC Chemical compound Cc(c1c(cc2N=S3(CCC3)=O)ncnc1Nc(ccc(F)c1)c1O[C@H](CO[C@@H]13)[C@H]1OC[C@H]3OC)c2OC VHVBDGHFDASHSR-OVSMBABESA-N 0.000 description 1
- RKJUWQKXKTYZTQ-UHFFFAOYSA-N NC1C(C2)OCCC2=[O]C1 Chemical compound NC1C(C2)OCCC2=[O]C1 RKJUWQKXKTYZTQ-UHFFFAOYSA-N 0.000 description 1
- CCZZYRVYMZCVNQ-JLLWLGSASA-N [O-][N+](c(c(O[C@H]1[C@H]2OCC[C@H]2OC1)c1)ccc1F)=O Chemical compound [O-][N+](c(c(O[C@H]1[C@H]2OCC[C@H]2OC1)c1)ccc1F)=O CCZZYRVYMZCVNQ-JLLWLGSASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14167373 | 2014-05-07 | ||
| PCT/EP2015/059453 WO2015169677A1 (en) | 2014-05-07 | 2015-04-30 | Sulfoximine substituted quinazolines for pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2749186T3 true ES2749186T3 (es) | 2020-03-19 |
Family
ID=50639371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15720077T Active ES2749186T3 (es) | 2014-05-07 | 2015-04-30 | Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10167296B2 (enExample) |
| EP (1) | EP3140300B1 (enExample) |
| JP (1) | JP6479854B2 (enExample) |
| AU (1) | AU2015257917C1 (enExample) |
| CA (1) | CA2944103A1 (enExample) |
| ES (1) | ES2749186T3 (enExample) |
| WO (1) | WO2015169677A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170066778A1 (en) * | 2015-09-04 | 2017-03-09 | Aunova Medchem LLC | Solubility for target compounds |
| WO2017165908A1 (en) * | 2016-03-31 | 2017-10-05 | South Australian Health And Medical Research Institute Limited | Method of inhibiting high fat diet-related conditions |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| SE0102147D0 (sv) | 2001-06-18 | 2001-06-18 | Pharmacia Ab | New methods |
| EP2277552A1 (en) | 2001-10-29 | 2011-01-26 | Boehringer Ingelheim International GmbH | Mnk kinase proteins and diabetes |
| GB0315587D0 (en) | 2003-07-03 | 2003-08-13 | Univ Dundee | Anti-inflammatory assay and compounds |
| MXPA06011589A (es) | 2004-04-08 | 2006-12-20 | Dow Agrosciences Llc | Sulfoximinas n-sustituidas insecticidas. |
| EP1746099A1 (en) | 2004-12-23 | 2007-01-24 | DeveloGen Aktiengesellschaft | Mnk1 or Mnk2 inhibitors |
| CA2655799A1 (en) * | 2005-06-22 | 2006-12-28 | Develogen Aktiengesellschaft | Thienopyrimidines for pharmaceutical compositions |
| WO2007104053A2 (en) | 2006-03-09 | 2007-09-13 | Pharmacopeia, Inc. | 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders |
| CN101466716A (zh) * | 2006-04-07 | 2009-06-24 | 德维洛根股份公司 | 用于药物组合物的具有mnkl/mnk2抑制活性的噻吩并嘧啶 |
| WO2007147874A1 (en) | 2006-06-22 | 2007-12-27 | Biovitrum Ab (Publ) | Pyridine and pyrazine derivatives as mnk kinase inhibitors |
| EP1889847A1 (en) * | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
| CA2687611A1 (en) * | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Novel sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors |
| UY32072A (es) * | 2008-08-26 | 2010-03-26 | Boehringer Ingelheim Int | Tienopirimidinas para composiciones farmacéuticas |
| WO2010117425A1 (en) | 2009-03-31 | 2010-10-14 | Biogen Idec Ma Inc. | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
| TW201111378A (en) | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
| UY33241A (es) * | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| TW201141872A (en) * | 2010-02-26 | 2011-12-01 | Boehringer Ingelheim Int | Cycloalkyl containing thienopyrimidines for pharmaceutical compositions |
| EA201201192A1 (ru) * | 2010-02-26 | 2013-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций |
| US9170933B2 (en) * | 2010-06-28 | 2015-10-27 | International Business Machines Corporation | Wear-level of cells/pages/sub-pages/blocks of a memory |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| ES2591129T3 (es) | 2012-05-21 | 2016-11-25 | Bayer Pharma Aktiengesellschaft | Tienopirimidinas |
| TW201412740A (zh) * | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
| CA2885783A1 (en) * | 2012-09-26 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases |
| ES2635262T3 (es) * | 2012-11-09 | 2017-10-03 | Evotec International Gmbh | Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas |
| WO2014118226A1 (en) * | 2013-02-01 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolopyrimidinylamino-indazoles |
| DK3013805T3 (en) * | 2013-06-28 | 2018-04-23 | Evotec Int Gmbh | Sulfoximine-substituted quinazolines and their use as MNK1 and / or MNK2 kinase inhibitors |
| JP6457523B2 (ja) * | 2013-12-04 | 2019-01-23 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 医薬組成物のためのスルホキシイミン置換キナゾリン |
-
2015
- 2015-04-30 CA CA2944103A patent/CA2944103A1/en active Pending
- 2015-04-30 WO PCT/EP2015/059453 patent/WO2015169677A1/en not_active Ceased
- 2015-04-30 JP JP2016566786A patent/JP6479854B2/ja not_active Expired - Fee Related
- 2015-04-30 US US15/308,712 patent/US10167296B2/en active Active
- 2015-04-30 EP EP15720077.5A patent/EP3140300B1/en active Active
- 2015-04-30 AU AU2015257917A patent/AU2015257917C1/en not_active Ceased
- 2015-04-30 ES ES15720077T patent/ES2749186T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015169677A1 (en) | 2015-11-12 |
| AU2015257917B2 (en) | 2017-08-17 |
| EP3140300B1 (en) | 2019-08-14 |
| JP6479854B2 (ja) | 2019-03-06 |
| EP3140300A1 (en) | 2017-03-15 |
| CA2944103A1 (en) | 2015-11-12 |
| JP2017514867A (ja) | 2017-06-08 |
| AU2015257917C1 (en) | 2019-03-14 |
| US20170260195A1 (en) | 2017-09-14 |
| US10167296B2 (en) | 2019-01-01 |
| AU2015257917A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2663788T3 (es) | Quinazolinas sustituidas con sulfoximina y su uso como inhibidores de MNK1 y/o MNK2 quinasas | |
| ES2635262T3 (es) | Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas | |
| EP2539346B1 (en) | 4-[heterocycloalkyloxy(hetero)arylamino] thieno[2,3-d]pyrimidines having mnk1/ mnk2 inhibiting activity for pharmaceutical compositions | |
| EP2539343B1 (en) | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions | |
| EP2331551B1 (en) | Thienopyrimidines for pharmaceutical compositions | |
| ES2749186T3 (es) | Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas | |
| WO2015091156A1 (en) | Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions | |
| EP3077383B1 (en) | Sulfoximine substituted quinazolines for pharmaceutical compositions |